{"id":2770,"date":"2023-12-06T00:56:05","date_gmt":"2023-12-06T00:56:05","guid":{"rendered":"https:\/\/economicherald.net\/?p=2770"},"modified":"2023-12-06T00:56:05","modified_gmt":"2023-12-06T00:56:05","slug":"asx-health-stocks-imugene-wins-intention-to-grant-cancer-vaccine-patent-phase-2-trial-in-2024","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=2770","title":{"rendered":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024"},"content":{"rendered":"<p>Imugene issued \u201cIntention to Grant\u201d notice by European Patent Office<br \/>\nThe patent will be given to its PD1-Vaxx cancer vaccine<br \/>\nThe company will begin PD1-Vaxx Phase 2 colorectal cancer clinical trial in 2024<\/p>\n<p>\u00a0<\/p>\n<p>Oncology biotech <strong><a href=\"https:\/\/stockhead.com.au\/company\/imugene-imu\/\">Imugene (ASX:IMU)<\/a><\/strong> rose 7% this morning after releasing a couple of announcements.<\/p>\n<p>The company said that the <strong>European Patent Office<\/strong> has issued a notification of <strong>\u201cIntention to Grant\u201d <\/strong> for Imugene\u2019s<strong> PD1-Vaxx cancer vaccine.<\/strong><\/p>\n<p>PD1-Vaxx is a first-in-class programmed death-1 (PD1) vaccine, currently in clinical development for non-small cell lung cancer (NSCLC) and in 2024, colorectal cancer.<\/p>\n<p>It was designed to treat tumours such as lung and colorectal cancer by interfering with the PD-1\/PD-L1 pathway, and produce an anti-cancer effect similar to <em>Tecentiq, Keytruda and Opdivo.<\/em><\/p>\n<p>The European patent application, which covers the manufacturing and method of treatment, is expected to proceed to grant in late 2023.\u00a0 Once granted, the patent will have a maximum term that will expire on 28 March 2038.<\/p>\n<p>Corresponding applications for PD1-Vaxx are pending in Canada, China, Hong Kong, India, South Korea, Brazil and Australia. The patent has previously received a Notice of Grant in the US and Japan.<\/p>\n<p>\u201cReceiving the notice that this European patent application will proceed to grant is an excellent milestone for the technology,\u201d said Imugene\u2019s CEO, Leslie Chong.<\/p>\n<p>\u201cAnd we are excited to continue developing the therapy to demonstrate the value of our PD1-Vaxx vaccine and to have a positive impact on the lives of many cancer patients.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Phase 2 study to commence in 2024<\/h2>\n<p>Meanwhile, Imugene also confirmed the <strong>PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial<\/strong> will commence in 2024.<\/p>\n<p>Approximately 10 sites \u2013 six in Australia and four in the UK \u2013 with approximately 44 patients will be enrolled in the study over about 18 months.<\/p>\n<p>The primary objective of the trial is to determine major pathological response rates (a measurement of tumour size), after treating with PD1-Vaxx before surgery to remove any residual tumour.<\/p>\n<p>Colorectal cancer, also known as bowel cancer, is the third most common cancer, with a worldwide annual incidence of over 1.2 million cases and a mortality rate of approximately 50%.<\/p>\n<p>It is estimated that a person has a 1 in 19 (or 5.2%) risk of being diagnosed with bowel cancer by the age of 85.<\/p>\n<p>\u201cWe are excited to commence this important Phase 2 trial with PD1-Vaxx after being approached by the leading colorectal cancer oncologists from both Australia and the UK,\u201d said Chong.<\/p>\n<p>\u201cThe study costs are partially funded being Investigator Sponsored studies, and fall within current cash flow forecasts,\u201d she added.<\/p>\n<p>\u00a0<\/p>\n<h2>Imugene share price today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-imugene-wins-intention-to-grant-cancer-vaccine-patent-phase-2-trial-in-2024\/\">ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Imugene issued \u201cIntention to Grant\u201d notice by European Patent Office The patent will be given to its PD1-Vaxx cancer vaccine The company will begin PD1-Vaxx <a href=\"https:\/\/economicherald.net\/?p=2770\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":2771,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=2770\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Imugene issued \u201cIntention to Grant\u201d notice by European Patent Office The patent will be given to its PD1-Vaxx cancer vaccine The company will begin PD1-Vaxx [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=2770\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-06T00:56:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024\",\"datePublished\":\"2023-12-06T00:56:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2770#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=2770\",\"name\":\"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg\",\"datePublished\":\"2023-12-06T00:56:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2770\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2770#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=2770","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald","og_description":"Imugene issued \u201cIntention to Grant\u201d notice by European Patent Office The patent will be given to its PD1-Vaxx cancer vaccine The company will begin PD1-Vaxx [more...]","og_url":"https:\/\/economicherald.net\/?p=2770","og_site_name":"Economic Herald","article_published_time":"2023-12-06T00:56:05+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=2770#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=2770"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024","datePublished":"2023-12-06T00:56:05+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=2770"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=2770#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=2770#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=2770","url":"https:\/\/economicherald.net\/?p=2770","name":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024 - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=2770#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=2770#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg","datePublished":"2023-12-06T00:56:05+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=2770#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=2770"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=2770#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Imugene-issued-Intention-to-Grant-notice-by-European-Patent-Office.-Picture-Getty-yk1Mx1.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=2770#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Imugene wins \u2018intention to grant\u2019 cancer vaccine patent, Phase 2 trial in 2024"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2770"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2770\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/2771"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}